JMDC Inc
Japanese healthcare data company selling anonymized medical claims and health records to insurers and drugmakers.
The call
JMDC keeps growing revenue on locked-in health data access, but profit slipped even as sales rose, and OMRON now controls the company's direction.
JMDC owns a huge database of anonymized medical claims and patient records from Japan's health insurers. It is very hard to copy because the company has 20-year agreements with insurance groups that legally lock in data sharing, and Japanese privacy law makes it nearly impossible for competitors like IQVIA or AI chatbots to access the same information without negotiating those same deals all over again. But there is a warning sign: the company's bottom-line profit fell 7 percent last year even though revenue and cash flow grew 20 percent or more, which suggests that artificial intelligence is making the analysis work cheaper and faster, squeezing the money JMDC makes from selling reports and data services. If this trend continues, JMDC's growth could feel hollow.
Why
01
AI pressure: Generative AI tools for claims analysis and report writing. AI can automate the report and analysis layer JMDC sells, but cannot get the licensed claims data itself. Could AI do the core job? Unlikely.
02
Bigger players: IQVIA / Fujitsu Japan. IQVIA has a Japan claims product but hasn't taken visible share; Fujitsu chose a partnership with JMDC in January 2026 instead of competing. Could a giant copy it? No, they are blocked.
03
What protects it. Two decades of consent agreements with Japanese health insurance associations that hand JMDC data no outsider can quickly copy.
What would change this call
JMDC's Q1 FY2027 earnings on August 5, 2026 show profit-to-owners trend. Would confirm whether the 7% profit decline is a one-year AI-investment blip or a structural margin squeeze.
IQVIA or Medical Data Vision announce a named client win in Japanese claims-data licensing. Would show a rival actually capturing JMDC's Healthcare Big Data customers.
OMRON issues another minority-shareholder-protection notice or moves toward a take-private. Would signal governance change or consolidation risk affecting JMDC's independence.
IQVIA or Medical Data Vision announce a named client win in Japanese claims-data licensing. Would show a rival actually capturing JMDC's Healthcare Big Data customers.
OMRON issues another minority-shareholder-protection notice or moves toward a take-private. Would signal governance change or consolidation risk affecting JMDC's independence.
Key numbers
- Revenue up 21% to ¥50.5 billion
- Profit to owners down 7% despite EBITDA up 21%
- 20M+ subjects, 1.573B claims in core database
Named risks
- Profit attributable to owners fell 7% YoY in FY2026 despite 20%+ revenue and EBITDA growth.
- OMRON's 54.19% controlling stake creates governance overhang, repeated minority-safeguard notices in June 2025 and 2026.
- Generative AI commoditizing analyst-driven RWD report generation and claims-cleaning services layer.
- Stock trades far below all-time high of ¥9,470, in a volatile ¥2,369-¥4,950 52-week range as of 2026-07-30.
- Potential regulatory shift opening kenpo claims data to open licensing could erode exclusive data moat.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Medical Data Vision (MDV) | contesting | Academic literature (2022-03-17) names JMDC and MDV as Japan's two dominant RWD sources, stable duopoly |
| IQVIA | losing to | IQVIA has a Japan claims offering but has not displaced JMDC/MDV duopoly as of 2026-07 |
| DeSC Healthcare | losing to | DeSC's claims database covers ~11.2M people vs JMDC's 16-20M as of 2023-12-23 |
| Fujitsu Japan | contesting | Fujitsu, Japan's top EHR vendor, chose partnership with JMDC in Jan 2026 rather than compete |
| OMRON Corporation | contesting | Controlling shareholder since Oct 2023 with 54.19% stake, could internalize JMDC's data capabilities |
Questions people ask
- What is JMDC's biggest risk?
- The main watch item is whether OMRON, which held 54.24% of JMDC's voting rights as of 2025-06-25, moves toward a full squeeze-out or delisting tender before the end of 2027. A second checkpoint is whether FY2027 consolidated revenue reaches the guided ¥60.5 billion by 2027-05, a target issued 2026-05-08 that represents 20% growth over FY2026.
- Is JMDC in financial trouble?
- No, the numbers point the other way: FY2026 EBITDA rose 21% to ¥13,178 million and revenue rose 21% to ¥50,462 million, both as of 2026-03-31. The Healthcare-Big Data segment, JMDC's core claims-analytics business, grew 24% to ¥44,070 million in the same period, and FY2027 guidance calls for another 20% revenue increase.
- Who are JMDC's biggest competitors?
- Within Japan's real-world-data landscape, JMDC is contested by Medical Data Vision, DeSC Healthcare, and IQVIA, alongside the government's more restrictive NDB claims dataset. JMDC operates the country's largest licensed database of health insurance claims, and no meaningful customer loss to these rivals is visible in the evidence as of the July 2026 assessment.
- Is JMDC at risk from AI?
- The evidence rates the AI threat as building rather than displacing, since generic AI tools can automate report-writing on top of claims data but cannot replicate JMDC's licensed 20-year claims archive. This means AI more often feeds into JMDC's analytics tools than replaces them, and JMDC's data access itself, not brand or scale, remains its main protection as of the July 2026 assessment.
- Could a big tech company or foreign data giant take over JMDC's market?
- The evidence marks this threat as not applicable, because no foreign or domestic data giant can enter Japan's claims market without certification under the 2017 Act. JMDC operates the country's largest licensed database of health insurance claims, a pipeline that competitors and AI tools cannot easily replicate, and Medical Data Vision occupies a stable, non-displacing position rather than a growing one as of the July 2026 assessment.
- What should I watch next for JMDC?
- Two dated checkpoints matter: JMDC's Q1 FY2027 earnings release expected in August 2026, and whether full-year FY2027 consolidated revenue reaches the guided ¥60.5 billion by 2027-05. Also worth tracking is whether OMRON, holder of 54.24% of voting rights as of 2025-06-25, advances any move toward a squeeze-out or delisting tender before the end of 2027.
Timeline
- 2026-06-25JMDC issues renewed notice on OMRON controlling-shareholder relationship and minority-investor safeguards
- 2026-05-08FY2026 results: revenue ¥50.462B (+20.9%), profit to owners falls 7% to ¥6.77B
- 2026-02-05JMDC and Fujitsu Japan announce AI and EHR data collaboration
- 2026-01-01Fujitsu Japan partnership begins, combining EHR data with JMDC claims models
- 2025-09-30Consolidated headcount reaches 2,281 employees, up 4.3% from March 2025
- 2025-06-25JMDC issues first formal notice on OMRON controlling-shareholder relationship
- 2025-05-01JMDC signs health-promotion data partnership with Yokosuka City
- 2025-02-01JMDC divests subsidiary Noah Medical System Co. to Kakehashi Co.
- 2023-10-16OMRON completes tender offer, becomes controlling shareholder with 54.19% voting rights
- 2002-01-31JMDC Inc. established
Revision history
30 July 2026
First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Company Profile (2026-06-24)
- Summary of Financial Statements FY ended March 31, 2026 (2026-05-08)
- JMDC boosts revenue and dividend as profit slips (2026-05-08)
- JMDC Investor Relations, Earnings Summary & Outlook (2026-05-08)
- Fujitsu Japan and JMDC announce collaboration (2026-02-05)
- JMDC Details Relationship With Omron as Controlling Shareholder (2026-06-25)
- JMDC Inc. Company Profile & Executives - WSJ
- gurufocus.com (2026-07-30)
- Earnings & Revenue Performance
- JMDC Claims Database (2026-01-22)
- Context and Considerations for Use of Two Japanese Real-World Databases (2022-03-17)
- JMDC Number of Employees (2026-06-27)